Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory processes in bronchial asthma.

R Beasley1, W Roche, S T Holgate

  • 1Medicine 1 and Pathology, Southampton General Hospital, United Kingdom.

Drugs
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A vanguard randomised feasibility trial comparing three regimens of peri-operative oxygen therapy on recovery after major surgery.

Anaesthesia·2023
Same author

COVID-19 border controls prevent a 2021 seasonal influenza epidemic in New Zealand.

Public health·2021
Same author

Fenoterol and Death from Asthma in New Zealand.

International archives of allergy and immunology·2021
Same author

Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study.

Respiratory medicine·2020
Same author

Obesity, underweight and BMI distribution characteristics of children by gross national income and income inequality: results from an international survey.

Obesity science & practice·2018
Same author

Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Inflammation in bronchial asthma is present even in clinically stable patients. Therefore, anti-inflammatory asthma treatments should extend beyond severe cases to address underlying inflammatory processes.

Area of Science:

  • Pulmonology
  • Immunology
  • Pathology

Background:

  • Bronchial asthma is characterized by chronic airway inflammation.
  • Pathological features include epithelial damage, goblet cell changes, collagen deposition, and immune cell infiltration.
  • These features are not exclusive to fatal asthma cases.

Purpose of the Study:

  • To investigate the presence and extent of inflammatory processes in clinically stable asthma.
  • To determine if pathological hallmarks of asthma are confined to severe or fatal disease.

Main Methods:

  • Histopathological examination of airway tissues.
  • Analysis of inflammatory cell infiltration and tissue remodeling markers.
  • Comparison of findings between stable and severe asthma cohorts.

Related Experiment Videos

Main Results:

  • Characteristic inflammatory features of asthma were observed in subjects with clinically stable asthma.
  • These pathological changes were not limited to patients with severe or fatal disease.
  • Evidence suggests a continuous inflammatory process across asthma severity spectrum.

Conclusions:

  • The underlying inflammatory processes in bronchial asthma are present in stable disease.
  • Pharmacological interventions targeting inflammation should be considered for a broader range of asthma patients, not just severe cases.
  • This supports a more inclusive approach to asthma management focusing on inflammation control.